Clinical effect of Roxadustat combined with basic therapy on patients with primary nephrotic syndrome complicated by acute kidney injury
Chen Xingqing
Chen Xinyi
Shen Bingbing
Wang Fang
Zhang Binying
Abstract：Objective To investigate the clinical effect of Roxadustat combined with basic therapy on patients with acute kid-ney injury(AKI) secondary co primary nephrotic syndrome(PNS)clinicaltherapy,providing a reference for therapy.Methods A total of 118 PNS patients with AKI treated between July 2022 and May 2023 were randomly assigned to control (basic therapy) or study (basic therapy plus Roxadustat) groups,59 patients in each group.The clinical effect,renal function indi-cators[serum creatinine (SCr),blood urea nitrogen (BUN),estimated glomerular filtration rate (eGFR)],24-hour urinary protein (24 h Upro),plasma albumin,blood lipid indicators[triglycerides (TG),total cholesterol (TC),low-density lipo-protein cholesterol (LDL-C),high-density lipoprotein cholesterol (HDL-C)],blood routine indices[white blood cells count (WBC),red blood cells count(RBC),hemoglobin (Hb),platelet count (PLT)],liver function indicators[albumin (ALB),alanine aminotransferase (ALT),aspartate aminotransferase (AST),and total bilirubin (TBIL)]before and after treatment were compared,followed by safety assessment.Results The overall response rate in the study group was significantly high-er than that in the control group[91.53％ (54/59) vs.77.97％ (46/59);x2=4.196,P=0.041].Analysis of variance showed significant differences in SCr,BUN,and eGFR between the two groups over different time points,and interactive effects with statistical significance were also identified (P<0.05).At 7,14,and 28 days,the study group had significantly lower SCr and BUN levels and higher eGFR than the control group (P<0.05).Significant differences were also observed in 24 h Upro,TC,and TG between groups over time (P<0.05).At 14 and 28 days,the study group had significantly lower 24 h Upro,TC,and TG levels and higher plasma albumin levels compared to the control group (P<0.05).No significant differences were found in LDL-C or HDL-C levels before and after treatment between the two groups (P>0.05).Addition-ally,there were no significant differences in WBC,RBC,Hb,PLT,ALB,ALT,AST,TBIL levels before and 28 days af-ter treatment between the two groups (P>0.05).The incidence of adverse reactions was 3.39％ (2/59) in the study group and 1.69％ (1/59) in the control group,with no significant difference (P>0.05).Conclusion Roxadustat combined with basic therapy effectively promotes renal function and lipid metabolism in PNS patients with AKI,with high medication safe-ty and minimal impact on liver function,suggesting clinical applicability.
Keywords：RoxadustatBasic therapyPrimary nephrotic syndromeAcute kidney injuryRenal functionBlood lipids
Publication Date：2024-04-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 33-38 )